Risk factors
Incannex Healthcare (IXHL) risk factors
Item 1A of every Incannex Healthcare Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors64 risks7 new3 dropped11 reworded
FDA layoffs and funding or staffing problems may delay Incannex’s drug reviews, approvals and inspections.
Filed Sep 25, 2026 - FY2025 10-K risk factors60 risks2 new7 dropped10 reworded
Incannex authorized a $20 million share repurchase program while noting risks from short sellers and potential Nasdaq delisting.
Filed Sep 29, 2025 - FY2024 10-K risk factors65 risks
Clinical-stage biopharmaceutical company focused on cannabinoid and psychedelic drug candidates with a going concern warning. Relies heavily on Australian R&D tax incentives and requires ongoing external funding. Subject to strict controlled substance laws and potential public controversy.
Filed Sep 30, 2024